AKT1 and acute myeloid leukemia: Since both standard AML induction chemotherapy and HMAs induce DSBs, which boost PI3K/AKT signaling in a DDR-dependent manner, the majority of AML patients treated with curative or non-curative therapeutic regimen will potentially benefit from complementary treatment with relevant small molecule inhibitors.